AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

MENLO PARK, Calif., October 21, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced the presentation of a poster detailing the design of its planned Phase 2 clinical trial evaluating epetraborole in patients with polycythemia vera (PV) at the 18th International Congress on Myeloproliferative Neoplasms being held October 29-30

AN2 Therapeutics to Participate at Upcoming November 2026 Investor Conferences

View the basic ANTX option chain and compare options of AN2 Therapeutics, Inc. on Yahoo Finance.

Gilbert Lynn Marks received immediately vested stock on October 12, 2026, under the non-employee director pay policy, bringing direct holdings to 84,156 shares.

The shares vested immediately on October 12, 2026, leaving Martin with 19,252 directly held shares under the non-employee director compensation policy.

Aziz Kabeer's award vested immediately on October 12, 2026, bringing his reported direct holdings to 61,571 shares under the director compensation policy.